Recognition of extraordinary profit from the sale of marketable securities. Gains from the sale are 524 million yen, period from 2026-06-18 to 2026-09-11, to be recognized as extraordinary profit in upcoming financial results. Also already reflected in earnings guidance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4531","jir_company_name":"Organic Synthesis Pharmaceuticals Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4531-20260918-01.pdf","jir_short_summary":"Recognition of extraordinary profit from the sale of marketable securities. Gains from the sale are 524 million yen, period from 2026-06-18 to 2026-09-11, to be recognized as extraordinary profit in upcoming financial results. Also already reflected in earnings guidance.","jir_summary":"### Overview\nThe notice published today states that, aiming to reduce strategically held shares and improve asset efficiency, four listed securities were disposed of, generating gains on sale of marketable securities. The sale period was from June 18, 2026 to September 11, 2026, with proceeds of 524 million yen. This gain is scheduled to be recorded as extraordinary profit in the second quarter of the fiscal year ending March 2027, and is noted to have already been reflected in the FY2027 earnings guidance.\n\n### Impact on shareholders and future outlook\nBecause this will be recorded as extraordinary profit, it will affect indicators such as net income for the current period. Gains are expected to be recognized as extraordinary profit in the interim period of FY2027, and it is emphasized that this has already been reflected in the guidance. Going forward, attention should be paid to disclosure in subsequent quarterly results and the performance of other business segments.","jir_financial_highlights":"Gain on sale of marketable securities: 524 \u767e\u4e07\u5186 (Unknown)","jir_category":"","jir_hashtags":"#OrganicSynthesisPharmaceuticals, #ExtraordinaryProfit, #SaleOfMarketableSecurities, #AssetEfficiency","jir_key_figures":"Gain on sale of marketable securities: 524 million yen (period: 2026\/6\/18\u20132026\/9\/11)\nFuture recognition: Extraordinary profit in the second quarter of FY2027\nIncorporation: Incorporated into FY2027 earnings guidance","jir_meta_title":"\u3010Organic Synthesis Pharmaceuticals\u3011Notice of Recording Extraordinary Profit\uff5c2026 September","jir_meta_description":"Organic Synthesis Pharmaceuticals records 524 million yen in extraordinary profit from the sale of marketable securities. Period: 2026\/6\/18\u20139\/11, to be recognized in the second quarter of FY2027. Forecast already reflected.","jir_og_title":"Organic Synthesis Pharmaceuticals Notice of Extraordinary Profit from Sale of Marketable Securities","jir_og_description":"Recording 524 million yen of extraordinary profit from the sale of marketable securities. Recognized as extraordinary profit in the second quarter of FY2027, already reflected in the forecast.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59377,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-115300","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n